These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical and investigational considerations for the use of IGIV therapy. Ballow M Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S12-8; quiz S19-21. PubMed ID: 16100383 [TBL] [Abstract][Full Text] [Related]
6. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Kaveri S; Prasad N; Vassilev T; Hurez V; Pashov A; Lacroix-Desmazes S; Kazatchkine M Mult Scler; 1997 Apr; 3(2):121-8. PubMed ID: 9291165 [TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465 [TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases]. Mouthon L; Hurez V; Kazatchkine M Ann Med Interne (Paris); 1993; 144(8):506-13. PubMed ID: 8179238 [TBL] [Abstract][Full Text] [Related]
9. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Daoud YJ; Amin KG Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922 [TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. Negi VS; Elluru S; Sibéril S; Graff-Dubois S; Mouthon L; Kazatchkine MD; Lacroix-Desmazes S; Bayry J; Kaveri SV J Clin Immunol; 2007 May; 27(3):233-45. PubMed ID: 17351760 [TBL] [Abstract][Full Text] [Related]
12. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Ahmed AR Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919 [TBL] [Abstract][Full Text] [Related]
13. Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases. Mouthon L; Kaveri S; Kazatchkine M Transfus Sci; 1994 Dec; 15(4):393-408. PubMed ID: 10155557 [TBL] [Abstract][Full Text] [Related]
14. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. Hurez V; Kaveri SV; Kazatchkine MD J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249 [TBL] [Abstract][Full Text] [Related]
15. [Immunomodulatory effects of intravenous immunoglobulins]. Kazatchkine M; Mouthon L; Kaveri SV Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S13-8. PubMed ID: 10896983 [TBL] [Abstract][Full Text] [Related]
16. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Emmi L; Chiarini F Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582 [TBL] [Abstract][Full Text] [Related]